Paired box protein Pax-3 (PAX3)

Paired box protein Pax-3 (PAX3) is a highly conserved transcription factor characterized by a paired box domain and a homeodomain, which together mediate sequence-specific DNA binding[1][4][6][7]. PAX3 plays a key regulatory role during embryonic development, particularly in the formation, survival, migration, and differentiation of neural crest cells and skeletomuscular lineages[4][5][1]. Germline mutations in PAX3 cause syndromic developmental disorders, most notably Waardenburg syndrome, marked by pigmentary and neural abnormalities. Chromosomal translocations involving PAX3—such as the PAX3-FOXO1 fusion—drive oncogenesis in soft tissue sarcomas (notably alveolar rhabdomyosarcoma) by converting PAX3 into a potent, deregulated transcriptional activator. In normal physiology, PAX3 regulates genes essential for cell proliferation, survival, differentiation, and migration, and is tightly controlled by alternative splicing, post-translational modifications, and interactions with other nuclear proteins[1][4][7]. While not currently the direct target of approved drugs, PAX3 and its fusion products remain important investigational and prognostic biomarkers in developmental biology and oncology.

Other names

Paired box gene 3PAX-3HuP2HUP2CDHSWS1WS3paired box homeotic gene 3paired domain gene 3paired domain gene HuP2transcriptional factor PAX3

In cancers like alveolar rhabdomyosarcoma, PAX3 fusion proteins (e.g., PAX3-FOXO1) act as aberrant transcriptional activators, driving tumorigenesis. Drugs under investigation seek to disrupt its DNA binding or downstream signaling[4]. Small molecules, RNA interference, or gene editing approaches are explored to inhibit PAX3 function or expression in disease models[4].